SCHEMBL15329883

SCHEMBL15329883

COC(=O)c1[nH]c2ccc(OC)cc2c1C=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 5/20 0.57
TUBB P07437 5/20 0.57
TUBA3C P0DPH7 5/20 0.57
TUBA1B P68363 5/20 0.57
TUBA4A P68366 5/20 0.57
TUBB4B P68371 5/20 0.57
TUBB3 Q13509 5/20 0.57
TUBB2A Q13885 5/20 0.57
TUBB8 Q3ZCM7 5/20 0.57
TUBA3E Q6PEY2 5/20 0.57
TUBA1A Q71U36 5/20 0.57
TUBA1C Q9BQE3 5/20 0.57
TUBB6 Q9BUF5 5/20 0.57
TUBB2B Q9BVA1 5/20 0.57
TUBB1 Q9H4B7 5/20 0.57
KDM4E B2RXH2 8/20 0.56
GAA P10253 7/20 0.56
ALDH1A1 P00352 5/20 0.56
MAPT P10636 5/20 0.56
HPGD P15428 4/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4877545 0.89 KDM4E (0.67) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29956404 0.87 KDM4E (0.59) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1429238 0.87 KDM4E (0.59) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL7250379 0.87 ALDH1A1 (0.73) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL37221912 0.87 ALDH1A1 (0.73) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL16756047 0.87 ALDH1A1 (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL16756019 0.85 ALDH1A1 (0.59) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL5392425 0.84 ALDH1A1 (0.55) KDM4EGAAALDH1A1MAPTHPGD
SCHEMBL3220939 0.84 MEN1 (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL22346709 0.83 KMT2A (0.54) KDM4EGAAALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
US-9061994-B1 Materials and methods useful to induce vacuolization, cell death, or a combination thereof THE UNIVERSITY OF TOLEDO (US) 2015-06-23 US disclosed
US-20150152049-A1 Materials And Methods Useful To Induce Vacuolization, Cell Death, Or A Combination Thereof THE UNIVERSITY OF TOLEDO (US) 2015-06-04 US disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152049-A1 Materials And Methods Useful To Induce Vacuolization, Cell Death, Or A Combination Thereof BECN1, BAD, BAX TUBB4A 131/4885TUBB 161/4885TUBA3C 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.